University of Cambridge Archives

NeoPhore

NeoPhore is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. NeoPhore’s drug target rationale is highly validated by genetic evidence in cancer patients and cellular models…. Read More

Paragraf

The Parkwalk Opportunities Fund and the Parkwalk-managed University of Cambridge Enterprise Fund V have invested in a £2.64m seed round in Paragraf Limited, a spin-out from the Department of Materials Science at the University of Cambridge. Paragraf focuses on… Read More

Predictimmune

We are delighted to announce that the University of Cambridge Enterprise Fund IV and the Parkwalk Opportunities Fund have closed an investment in Predictimmune Limited, a spinout company from the University of Cambridge. Predictimmune is developing prognostic tests… Read More

Focal Point Positioning

The University of Cambridge Enterprise Fund IV has invested in Focal Point Positioning Limited, a spin-out from the University of Cambridge. Focal Point has developed software which offers highly accurate positioning of smartphones both indoors and outdoors in urban… Read More

Polypharmakos

Cambridge and Kew join forces to find new antimicrobial substances in plants The Parkwalk-managed University of Cambridge Enterprise Fund IV and Cambridge Enterprise have invested £500k in Polypharmakos Limited, a spin-out from the University of Cambridge and the… Read More

Healthera

Healthera Ltd, a provider of next-generation, pharmacy-integrated personal health management solutions, has secured seed investment from the University of Cambridge, the University of Cambridge Enterprise Fund III, FT Capital and high net worth individuals. The specific amounts are… Read More

PervasID

PervasID is developing a high reliability, wide area passive RFID system with the potential to provide location capability based on the EPC Class1 Gen2 standard. Spun out from research activity in the Engineering Department at the University of… Read More

PsyOmics

PsyOmics is a University of Cambridge spin-out working to improve the prevention, diagnosis and treatment of neuropsychiatric disorders. Mental illness accounts for over 15% of the disease burden in developed countries and in England alone, mental illness costs over… Read More

8Power

8Power is a University of Cambridge start-up developing novel technology for sensing and measurement in industrial applications. The University of Cambridge is a world leader in the science and technology of sensing, and is pioneering the research of new… Read More

Cambridge Touch Technologies

Cambridge Touch Technologies (CTT) is a University of Cambridge start-up developing next-gen 3D touch technology. CTT’s next generation 3D touch technology enables mobile devices to sense both the location and force of multi-touch inputs. CTT’s technology improves on… Read More

Silicon Microgrvity

Spun-out of the University of Cambridge Nanoscience Centre, Silicon Microgravity is commercialising a sensor technology which provides a breakthrough in the management of oil and gas reservoirs. The company’s breakthrough sensing technology combines the recording of gravity data at… Read More

GeoSpock

GeoSpock, a spin-out from the University of Cambridge, provides a real-time scaleable database for rapidly changing complex data. The company’s ambition is to become the Google Search of Big Data. GeoSpock’s technology platform sits at the base of an… Read More

Cytora

Founded in early 2013, Cytora has built an event detection technology that can detect factual, real world events in unstructured text. The technology can be scaled to cover all major event categories and be monetised across the Financial… Read More

Quethera

Quethera, a spin-out from the University of Cambridge, is a gene therapy company developing a novel treatment for glaucoma. The company aims to deliver gene products for neuroprotectants and their receptors directly to the eye, which will provide long term… Read More

Reduse

The Parkwalk-managed University of Cambridge Enterprise Fund III invested in Reduse in June 2015. In October 2016 the company entered voluntary liquidation. Reduse, a spin out from the Low Carbon Materials Processing Group at the University of Cambridge,… Read More

PhoreMost

PhoreMost has developed a next-generation phenotypic screening platform called ‘Site-Seeker’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for… Read More

University of Cambridge